drugset / Trial / NCT06427239
Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
Non-randomizedSequentialOpen-labelTreatment
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of HRS-4642 combined with adebrelimab, or with adebrelimab and other antitumor agents in patients with advanced pancreatic ductal adenocarcinoma (PDAC).
Timeline
- Start
- 2024-06-17
- Primary completion
- 2027-06
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Faminitib | Unknown | — | — |
| Subject | HRS-4642 | Unknown | — | — |
| Subject | SHR-8068 | Monoclonal antibody | — | — |